The differential or concurrent expression of CD44 and CD24 markers has been used for identification of cancer stem cells (CSCs) in a variety of human epithelial [36, 37] and sarcomatoid renal cell carcinoma [38] malignancies. This evidence concerns the gene CD44 and cancer.